Karin M. A. Swart

ORCID: 0000-0003-2521-5780
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bone health and osteoporosis research
  • Folate and B Vitamins Research
  • Vitamin D Research Studies
  • Nutrition and Health in Aging
  • Nutrition, Genetics, and Disease
  • Pharmaceutical Practices and Patient Outcomes
  • Nutritional Studies and Diet
  • Hip and Femur Fractures
  • Genetic Associations and Epidemiology
  • Health Systems, Economic Evaluations, Quality of Life
  • Balance, Gait, and Falls Prevention
  • Blood Pressure and Hypertension Studies
  • Cardiovascular Health and Disease Prevention
  • Chronic Disease Management Strategies
  • Pregnancy and Medication Impact
  • SARS-CoV-2 and COVID-19 Research
  • Vitamin C and Antioxidants Research
  • Pharmacological Effects and Toxicity Studies
  • Genetic and phenotypic traits in livestock
  • Cerebral Palsy and Movement Disorders
  • COVID-19 Clinical Research Studies
  • Diet and metabolism studies
  • Esophageal and GI Pathology
  • Bone and Joint Diseases
  • Fluoride Effects and Removal

Pharmo Institute
2021-2025

Amsterdam UMC Location Vrije Universiteit Amsterdam
2013-2025

Vrije Universiteit Amsterdam
2010-2024

Amsterdam University Medical Centers
2014-2024

Public Health Service of Amsterdam
2022-2023

Netcare Unitas Hospital
2019-2020

Stichting Artsenlaboratorium en Trombosedienst
2018-2019

University Medical Center
2013-2018

University Hospital and Clinics
2018

Amsterdam Public Health
2011-2017

10.1007/s00198-023-07012-1 article EN Osteoporosis International 2024-01-17

This study reports on the emergence of OXA-48-like carbapenemases among isolates Enterobacteriaceae in South Africa. In addition, during therapy a colistin-resistant OXA-181-producing Klebsiella pneumoniae isolate was documented following selective digestive tract decontamination with oral colistin, which is therefore strongly discouraged.

10.1128/jcm.02234-12 article EN Journal of Clinical Microbiology 2012-11-15

High homocysteine (HCY) levels are a risk factor for osteoporotic fracture. Furthermore, bone quality and strength compromised by elevated HCY owing to its negative impact on collagen maturation. is cleared cystathionine β-synthase (CBS), the first enzyme in transsulfuration pathway. CBS converts cystathionine, thereby committing it cysteine synthesis. A microarray experiment MC3T3-E1 murine preosteoblasts treated with 1,25-dihydroxyvitamin D(3) [1,25(OH)(2) ] revealed cluster of genes...

10.1002/jbmr.493 article EN Journal of Bone and Mineral Research 2011-08-23

Osteoporosis is a major health problem, and the economic burden expected to rise due an increase in life expectancy throughout world. Current observational evidence suggests that elevated homocysteine concentration poor vitamin B12 folate status are associated with increased fracture risk. As intake play large role metabolism, it hypothesized supplementation these B-vitamins will reduce incidence elderly people concentration.The B-PROOF (B-Vitamins for PRevention Of Osteoporotic Fractures)...

10.1186/1471-2318-11-80 article EN cc-by BMC Geriatrics 2011-12-01

We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cognitive performance in elderly people with elevated homocysteine (Hcy) levels.This multicenter, double-blind, randomized, placebo-controlled trial included 2,919 participants (65 years older) Hcy levels between 12 50 µmol/L. Participants received daily either a tablet 400 µg 500 (B-vitamin group) or placebo tablet. Both tablets contained 15 D3. Data were available for global functioning assessed by...

10.1212/wnl.0000000000001050 article EN Neurology 2014-11-13

Abstract Background: Folic acid and vitamin B12 play key roles in one-carbon metabolism. Disruption of metabolism may be involved the risk cancer. Our aim was to assess long-term effect supplementation with both folic on incidence overall cancer colorectal B Vitamins for Prevention Osteoporotic Fractures (B-PROOF) trial. Methods: Long-term follow-up B-PROOF trial participants (N = 2,524), a multicenter, double-blind randomized placebo-controlled designed 2 3 years daily (400 μg) (500 versus...

10.1158/1055-9965.epi-17-1198 article EN Cancer Epidemiology Biomarkers & Prevention 2018-10-19

Lowering elevated plasma homocysteine (Hcy) concentrations by supplementing vitamin B12 and folic acid may reduce depressive symptoms improve health-related quality of life (HR-QoL) in older adults. This study aimed to test this hypothesis a randomized controlled trial. Participants (N = 2919, ≥65 years, Hcy ≥12 µmol/L) received either 500 µg 400 daily or placebo for two years. Both tablets contained 15 D₃. Depressive were measured with the Geriatric Depression Scale-15 (GDS-15). HR-QoL was...

10.3390/nu8110748 article EN Nutrients 2016-11-23

ABSTRACT Population screening for fracture risk may reduce the incidence. In this randomized pragmatic trial, SALT Osteoporosis Study (SOS), we studied whether and subsequent treatment in primary care can fractures compared with usual care. A total of 11,032 women aged 65 to 90 years ≥1 clinical factor were individually (n = 5575) or 5457). Participants group underwent a program, including bone densitometry vertebral assessment. high 10-year probability (FRAX) offered anti-osteoporosis...

10.1002/jbmr.3815 article EN cc-by Journal of Bone and Mineral Research 2019-06-20

In 2019, the Innovative Medicines Initiative (IMI) funded ConcePTION project—Building an ecosystem for better monitoring and communicating safety of medicines use in pregnancy breastfeeding: validated regulatory endorsed workflows fast, optimised evidence generation—with vision that there is a societal obligation to rapidly reduce uncertainty about medication breastfeeding. The present paper introduces set concepts used describe European data sources involved project illustrates Common Data...

10.1002/cpt.2476 article EN Clinical Pharmacology & Therapeutics 2021-11-26

Abstract Background People living with chronic obstructive pulmonary disease (COPD) have an increased risk of experiencing cardiovascular (CV) events, particularly after exacerbation. Such CV burden is not yet known for incident COPD patients. We examined the severe events in patients periods following either moderate and/or exacerbations. Methods Persons aged ≥ 40 years diagnosis from PHARMO Data Network were included. Exposed time included 1–7, 8–14, 15–30, 31–180 and 181–365 days Moderate...

10.1186/s12931-023-02601-4 article EN cc-by Respiratory Research 2023-11-21
Coming Soon ...